camostat has been researched along with Proteinuria in 11 studies
camostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients.
Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effects of camostat mesilate (CM), a derivative of gabexate mesilate developed for oral use, on primary glomerulonephritis (GN) and chance hematuria and/or proteinuria were evaluated." | 9.11 | Effect of oral camostat mesilate on hematuria and/or proteinuria in children. ( Asami, T; Tomisawa, S; Uchiyama, M, 2004) |
| " We previously demonstrated that a high-salt (HS) diet provoked hypertension and proteinuria in Dahl salt-sensitive (DS) rats, accompanied by γENaC activation, which were attenuated by camostat mesilate (CM), an SP inhibitor." | 8.31 | A Serine Protease Inhibitor, Camostat Mesilate, Suppresses Urinary Plasmin Activity and Alleviates Hypertension and Podocyte Injury in Dahl Salt-Sensitive Rats. ( Adachi, M; Deng, Q; Iwata, Y; Izumi, Y; Kakizoe, Y; Kuwabara, T; Miyasato, Y; Mukoyama, M; Nagayoshi, Y; Nakagawa, M; Nakagawa, T; Narita, Y; Nishiguchi, K, 2023) |
| " Previously, we reported that a synthetic serine protease inhibitor, camostat mesilate (CM), mitigated hypertension and proteinuria in rodent disease models." | 8.02 | A serine protease inhibitor camostat mesilate prevents podocyte apoptosis and attenuates podocyte injury in metabolic syndrome model rats. ( Adachi, M; Deng, Q; Hayata, M; Iwata, Y; Izumi, Y; Kakizoe, Y; Kitamura, K; Kuwabara, T; Miyasato, Y; Miyoshi, T; Mizumoto, T; Morinaga, J; Mukoyama, M; Nakagawa, T; Sakai, Y; Tomita, K; Uchimura, K, 2021) |
| "Camostat mesilate, a developed derivative of gabexate mesilate for oral use, was administered in a daily dose of 600 mg for 4 weeks to 17 patients with heavy proteinuria due to various nephropathies." | 7.67 | Effect of camostat mesilate on heavy proteinuria in various nephropathies. ( Futaki, G; Hotta, O; Kurosawa, K; Matsubara, M; Suzuki, K; Taguma, Y, 1989) |
| "The effects of camostat mesilate (CM), a derivative of gabexate mesilate developed for oral use, on primary glomerulonephritis (GN) and chance hematuria and/or proteinuria were evaluated." | 5.11 | Effect of oral camostat mesilate on hematuria and/or proteinuria in children. ( Asami, T; Tomisawa, S; Uchiyama, M, 2004) |
| " We previously demonstrated that a high-salt (HS) diet provoked hypertension and proteinuria in Dahl salt-sensitive (DS) rats, accompanied by γENaC activation, which were attenuated by camostat mesilate (CM), an SP inhibitor." | 4.31 | A Serine Protease Inhibitor, Camostat Mesilate, Suppresses Urinary Plasmin Activity and Alleviates Hypertension and Podocyte Injury in Dahl Salt-Sensitive Rats. ( Adachi, M; Deng, Q; Iwata, Y; Izumi, Y; Kakizoe, Y; Kuwabara, T; Miyasato, Y; Mukoyama, M; Nagayoshi, Y; Nakagawa, M; Nakagawa, T; Narita, Y; Nishiguchi, K, 2023) |
| " Previously, we reported that a synthetic serine protease inhibitor, camostat mesilate (CM), mitigated hypertension and proteinuria in rodent disease models." | 4.02 | A serine protease inhibitor camostat mesilate prevents podocyte apoptosis and attenuates podocyte injury in metabolic syndrome model rats. ( Adachi, M; Deng, Q; Hayata, M; Iwata, Y; Izumi, Y; Kakizoe, Y; Kitamura, K; Kuwabara, T; Miyasato, Y; Miyoshi, T; Mizumoto, T; Morinaga, J; Mukoyama, M; Nakagawa, T; Sakai, Y; Tomita, K; Uchimura, K, 2021) |
| "Effect of serine protease inhibitor Camostat Mesilate (Foipan) on primary glomerulonephritis and it's mechanism were evaluated." | 3.68 | [Effect of protease inhibitor on primary glomerulonephritis and the mechanism of the effect]. ( Fukushima, M; Haramoto, T; Kumagai, I; Makino, H; Murakami, K; Ogura, T; Onbe, T; Ota, Z; Wada, J, 1991) |
| "Camostat mesilate, a developed derivative of gabexate mesilate for oral use, was administered in a daily dose of 600 mg for 4 weeks to 17 patients with heavy proteinuria due to various nephropathies." | 3.67 | Effect of camostat mesilate on heavy proteinuria in various nephropathies. ( Futaki, G; Hotta, O; Kurosawa, K; Matsubara, M; Suzuki, K; Taguma, Y, 1989) |
| "The number of the chronic renal failure (CRF) patients is increasing explosively." | 1.38 | Effect of a serine protease inhibitor on the progression of chronic renal failure. ( Adachi, M; Hayata, M; Kakizoe, Y; Kitamura, K; Miyoshi, T; Mizumoto, T; Morinaga, J; Onoue, T; Sakai, Y; Shiraishi, N; Tomita, K; Uchimura, K; Ueda, M; Yamazoe, R, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 6 (54.55) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Iwata, Y | 2 |
| Deng, Q | 2 |
| Kakizoe, Y | 3 |
| Nakagawa, T | 2 |
| Miyasato, Y | 2 |
| Nakagawa, M | 1 |
| Nishiguchi, K | 1 |
| Nagayoshi, Y | 1 |
| Narita, Y | 1 |
| Izumi, Y | 2 |
| Kuwabara, T | 2 |
| Adachi, M | 3 |
| Mukoyama, M | 2 |
| Mizumoto, T | 2 |
| Uchimura, K | 2 |
| Hayata, M | 2 |
| Morinaga, J | 2 |
| Miyoshi, T | 2 |
| Sakai, Y | 2 |
| Tomita, K | 2 |
| Kitamura, K | 2 |
| Yamazoe, R | 1 |
| Onoue, T | 1 |
| Ueda, M | 1 |
| Shiraishi, N | 1 |
| Asami, T | 1 |
| Tomisawa, S | 1 |
| Uchiyama, M | 1 |
| Ueda, Y | 1 |
| Nagasawa, K | 1 |
| Tsukamoto, H | 1 |
| Horiuchi, T | 1 |
| Yoshizawa, S | 1 |
| Tsuru, T | 1 |
| Furugo, I | 1 |
| Niho, Y | 1 |
| Matsubara, M | 3 |
| Taguma, Y | 3 |
| Saito, T | 2 |
| Yoshinaga, K | 2 |
| Onbe, T | 2 |
| Makino, H | 2 |
| Haramoto, T | 1 |
| Wada, J | 1 |
| Ogura, T | 1 |
| Kumagai, I | 2 |
| Murakami, K | 2 |
| Fukushima, M | 1 |
| Ota, Z | 2 |
| Nakayama, S | 1 |
| Koide, H | 1 |
| Kurosawa, K | 1 |
| Hotta, O | 1 |
| Suzuki, K | 1 |
| Futaki, G | 1 |
3 trials available for camostat and Proteinuria
| Article | Year |
|---|---|
Effect of oral camostat mesilate on hematuria and/or proteinuria in children.
Topics: Administration, Oral; Adolescent; Biopsy; Child; Child, Preschool; Esters; Female; Follow-Up Studies | 2004 |
Urinary C4 excretion in systemic lupus erythematosus.
Topics: Adolescent; Adult; Blotting, Western; Complement Activation; Complement C4; DNA; Esters; Female; Gab | 1995 |
Anti-proteinuric and anti-coagulatory effects of camostat mesilate in azotemic diabetics.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Blood Coagulation; Captopril; | 1992 |
8 other studies available for camostat and Proteinuria
| Article | Year |
|---|---|
A Serine Protease Inhibitor, Camostat Mesilate, Suppresses Urinary Plasmin Activity and Alleviates Hypertension and Podocyte Injury in Dahl Salt-Sensitive Rats.
Topics: Animals; Blood Pressure; Fibrinolysin; Hypertension; Kidney; Podocytes; Proteinuria; Rats; Rats, Inb | 2023 |
A serine protease inhibitor camostat mesilate prevents podocyte apoptosis and attenuates podocyte injury in metabolic syndrome model rats.
Topics: Animals; Apoptosis; Cells, Cultured; Disease Models, Animal; Esters; Guanidines; Hypertension; Male; | 2021 |
Effect of a serine protease inhibitor on the progression of chronic renal failure.
Topics: Animals; Creatinine; Disease Progression; Esters; Gabexate; Guanidines; Kidney; Kidney Failure, Chro | 2012 |
Effect of camostat mesilate on persistent proteinuria of IgA nephropathy.
Topics: Administration, Oral; Adult; Esters; Female; Gabexate; Glomerulonephritis, IGA; Guanidines; Humans; | 1992 |
[Effect of protease inhibitor on primary glomerulonephritis and the mechanism of the effect].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Urea Nitrogen; Complement System Proteins; Creatin | 1991 |
A proteinase inhibitor reduces proteinuria in nephrotic syndrome.
Topics: Esters; Gabexate; Guanidines; Humans; Nephrotic Syndrome; Protease Inhibitors; Proteinuria | 1991 |
[Clinical application of proteinase inhibitors to renal diseases].
Topics: Antithrombins; Esters; Free Radical Scavengers; Gabexate; Guanidines; Humans; Kidney Diseases; Prote | 1991 |
Effect of camostat mesilate on heavy proteinuria in various nephropathies.
Topics: Administration, Oral; Adolescent; Adult; Aged; Esters; Female; Gabexate; Glomerulonephritis; Glycosu | 1989 |